Open AccessA COVID-19 Case Complicated by Candida dubliniensis and Klebsiella pneumoniae-Carbapenem-Resistant Enterobacteriaceae
Author(s) -
Harith Alataby,
Francis Atemnkeng,
Sandeep S. Bains,
Foma Munoh Kenne,
Keith Diaz,
Jay Nfonoyim
Publication year - 2020
Publication title -
journal of medical cases
Language(s) - English
Resource type - Journals
eISSN - 1923-4163
pISSN - 1923-4155
DOI - 10.14740/jmc3588
Subject(s) - medicine , klebsiella pneumoniae , candida dubliniensis , microbiology and biotechnology , meropenem , pneumonia , streptococcus pneumoniae , klebsiella pneumonia , enterobacteriaceae , mycoplasma pneumoniae , immunosuppression , virology , antibiotics , pseudomonas aeruginosa , biology , antibiotic resistance , escherichia coli , bacteria , biochemistry , genetics , corpus albicans , gene , antifungal , dermatology
There has been increasing evidence of co-infections with coronavirus disease 2019 (COVID-19) pneumonia, which increases the severity of the disease. Organisms such as Klebsiella pneumoniae and Streptococcus pneumoniae have been previously isolated. We present a case of a COVID-19 patient treated with baricitinib and dexamethasone who later developed Klebsiella pneumoniae -carbapenem-resistant Enterobacteriaceae (CRE) and Candida dubliniensis bloodstream infections, treated with meropenem/vaborbactam and micafungin, respectively. These infections are exceedingly rare and are mostly reported in immunosuppressed patients. The finding of these bloodstream infections raises concerns on the cause of immunosuppression in this patient infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) treated with baricitinib and dexamethasone. There has been no report so far of COVID-19 associated with these co-infections.